CMS shortens list of drugs subject to new Medicare rebates in 2025
Bill Oxford/iStock via Getty Images


CMS has shortened a list of drugs whose makers will be required to pay additional rebates to Medicare beginning in 2025 due to price increases growing faster than inflation.
Last month, CMS provided a list of 27 drugs that companies would have to make additional rebates on, part of the Inflation Reduction Act's attempt to lower drug prices. The number is now down to 20 drugs.

Although companies will have to pay rebates for 2023 and 2024, they aren't due until 2025. Biopharma Dive first broke the story about the drug list changes.
Perhaps the two most significant drugs removed from the list are Gilead Sciences' (NASDAQ:GILD) Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), both of which are CAR-T therapies.
Bausch + Lomb's (NYSE:BLCO) macular edema treatment Xipere (triamcinolone acetonide) was also taken off.
Pfizer (NYSE:PFE) wasn't so lucky. None of its five drugs on the initial list were removed. These include Fragmin (dalteparin) and Atgam (lymphocyte immune globulin).
Under the Inflation Reduction Act, Medicare will also be able to start negotiating drug prices in 2026.